Document:

exv4w5

Exhibit 4.5

THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF
1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AND PURSUANT TO THE
PROVISIONS OF ARTICLE 5 BELOW, MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR
HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND APPLICABLE STATE SECURITIES LAW OR, IN
THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER OF THESE SECURITIES,
SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION IS EXEMPT FROM REGISTRATION.

WARRANT TO PURCHASE STOCK

Company: NuPathe, Inc., a Delaware corporation

Number of Shares: As set forth below

Class of Stock: Series B Preferred Stock, $0.001 par value per share

Warrant Price: $0.93, subject to adjustment as set forth herein

Issue Date: May 13, 2010

Expiration Date: May 13, 2020

	Credit Facility:  	This Warrant is issued in connection with that certain
Loan and Security Agreement of even date herewith by and
among MidCap Funding III, LLC, Silicon Valley Bank and
the Company (as amended and in effect from time to time,
the “Loan Agreement”).

     THIS WARRANT CERTIFIES THAT, for good and valuable consideration, SILICON VALLEY BANK
(together with any successor or permitted assignee or transferee of this Warrant or of any Shares
issued upon exercise or conversion hereof, “Holder”) is entitled to purchase the number of fully
paid and non-assessable shares (the “Shares”) of the above-stated Class of Stock (the “Class”) of
the above-named company (the “Company”) at the above-stated Warrant Price per Share, all as set
forth above and as adjusted pursuant to Article 2 of this Warrant, subject to the provisions and
upon the terms and conditions set forth in this Warrant.

     A. Number of Shares. Upon each Term Loan (as defined in the Loan Agreement) made by
Holder (or its affiliate) to the Company under the Loan Agreement, this Warrant automatically shall
become exercisable for such number of shares of the Class (cumulatively, the “Shares”) as shall
equal (a)(i) 0.0475, multiplied by (ii) the original principal amount of such Term Loan made by
Holder (or its affiliate), divided by (b) the Warrant Price in effect on and as of the date of such
Term Loan, and subject to adjustment thereafter from time to time in accordance with the provisions
of this Warrant.

ARTICLE 1. EXERCISE.

          1.1 Method of Exercise. Holder may exercise this Warrant by delivering the original
of this Warrant together with a duly executed Notice of Exercise in substantially the form attached
as Appendix 1 to the principal office of the Company. Unless Holder is exercising the conversion
right set forth in Article 1.2, Holder shall also deliver to the Company a check, wire transfer (to
an account designated by the

 

 

Company), or other form of payment acceptable to the Company for the aggregate Warrant Price for
the Shares being purchased.

          1.2 Conversion Right. If the fair market value of one Share (as determined pursuant
to Article 1.3) is greater than the Warrant Price (at the date of such calculation), then in lieu
of exercising this Warrant as specified in Article 1.1, Holder may from time to time convert this
Warrant, in whole or in part, into a number of Shares determined by dividing (a) the aggregate fair
market value of the Shares or other securities otherwise issuable upon exercise of this Warrant
minus the aggregate Warrant Price of such Shares by (b) the fair market value of one Share. The
fair market value of the Shares shall be determined pursuant to Article 1.3.

          1.3 Fair Market Value. If the Company’s common stock is traded in a public market and
the Shares are common stock, the fair market value of a Share shall be the closing price of a share
of common stock reported for the business day immediately before Holder delivers this Warrant
together with its Notice of Exercise to the Company (or in the instance where the Warrant is
exercised immediately prior to the effectiveness of the Company’s initial public offering (“IPO”),
the initial public offering price as set forth in the final prospectus relating to such offering).
If the Company’s common stock is traded in a public market and the Shares are preferred stock, the
fair market value of a Share shall be the closing price of a share of the Company’s common stock
reported for the business day immediately before Holder delivers this Warrant together with its
Notice of Exercise to the Company (or, in the instance where the Warrant is exercised immediately
prior to the effectiveness of the IPO, the initial public offering price as set forth in the final
prospectus relating to such offering), in both cases, multiplied by the number of shares of the
Company’s common stock into which a Share is convertible. If the Company’s common stock is not
traded in a public market, the Board of Directors of the Company shall determine fair market value
in its reasonable good faith judgment.

          1.4 Delivery of Certificate and New Warrant. Promptly after Holder exercises or
converts this Warrant and, if applicable, the Company receives payment of the aggregate Warrant
Price, the Company shall deliver to Holder certificates for the Shares acquired and, if this
Warrant has not been fully exercised or converted and has not expired, a new warrant of like tenor
representing the Shares not so acquired.

          1.5 Replacement of Warrants. On receipt of evidence reasonably satisfactory to the
Company of the loss, theft, destruction or mutilation of this Warrant and, in the case of loss,
theft or destruction, on delivery of an indemnity agreement reasonably satisfactory in form and
amount to the Company or, in the case of mutilation, on surrender and cancellation of this Warrant,
the Company shall execute and deliver, in lieu of this Warrant, a new warrant of like tenor.

          1.6 Treatment of Warrant Upon Acquisition of Company.

               1.6.1 “Acquisition”. For the purpose of this Warrant, “Acquisition” means any sale or
other disposition of all or substantially all of the assets of the Company, or any reorganization,
consolidation, merger, or sale of outstanding equity securities of the Company by the holders
thereof, where the holders of the Company’s outstanding voting equity securities as of immediately
before the transaction beneficially

2

 

own less than a majority of the outstanding voting equity securities of the surviving or successor
entity as of immediately after the transaction.

               1.6.2 Treatment of Warrant at Acquisition.

A) Holder agrees that, in the event of an Acquisition in which the sole consideration is cash
and/or Marketable Securities, this Warrant shall terminate on and as of the closing of such
Acquisition to the extent not previously exercised. The Company shall provide Holder with written
notice of any proposed Acquisition not later than ten (10) days prior to the closing thereof
setting forth the material terms and conditions thereof, and shall provide Holder with copies of
the draft transaction agreements and other documents in connection therewith and with such other
information respecting such proposed Acquisition as may reasonably be requested by Holder.

B) Upon the closing of any Acquisition other than as particularly described in subsection (A)
above, the surviving or successor entity shall assume this Warrant and the obligations of the
Company hereunder, and this Warrant shall, from and after such closing, be exercisable for the same
class, number and kind of securities, cash and other property as would have been paid for or in
respect of the Shares issuable (as of immediately prior to such closing) upon exercise in full
hereof as if such Shares had been issued and outstanding on and as of such closing, at an aggregate
Warrant Price equal to the aggregate Warrant Price in effect as of immediately prior to such
closing; and subject to further adjustment thereafter from time to time in accordance with the
provisions of this Warrant.

C) As used in this Article 1.6, “Marketable Securities” means securities meeting all of the
following requirements: (i) the issuer thereof is then subject to the reporting requirements of
Section 13 or Section 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), and is then current in its filing of all required reports and other information under the
Act and the Exchange Act; (ii) the class and series of shares or other security of the issuer that
would be received by Holder in connection with the Acquisition were Holder to exercise or convert
this Warrant on or prior to the closing thereof is then traded on a national securities exchange or
over-the-counter market, and (iii) Holder would not be restricted by contract or by applicable
federal and state securities laws from publicly re-selling, within six (6) months and one day
following the closing of such Acquisition, all of the issuer’s shares and/or other securities that
would be received by Holder in such Acquisition were Holder to exercise or convert this Warrant in
full on or prior to the closing of such Acquisition.

          1.7 Put Option.

               1.7.1 Holder shall have the right, but not the obligation, to require the Company to purchase
from Holder (“Put Option”) some or all of this Warrant at any time (i) upon or immediately prior to
the occurrence of the closing of an Acquisition, or liquidation, dissolution or winding up of the
Company, or (ii) upon, following or immediately prior to the occurrence of (1) any “Event of
Default” (as such term is defined in the Loan Agreement), or (2) maturity of the Obligations (as
defined in the Loan Agreement) (each of the events described in clauses (i) and (ii) of this
Article 1.7.1 a “Trigger Event”). The purchase price to the Company therefor (“Put Price”) shall
be equal to (x)(i) the then-fair market value of a Share (as determined in accordance with Article
1.3 above), less (ii) the then-effective Warrant Price, multiplied by (y) the

3

 

aggregate number of Shares issuable upon exercise or conversion hereof as to which Holder has
exercised the Put Option.

               1.7.2 The Put Option may be exercised by written notice given by Holder to the Company: (a) in
connection with a Trigger Event described in Article 1.7.1(i) above, within twenty (20) days
following Holder’s receipt of written notice of such Trigger Event (but in no event later than
three (3) days prior to the closing of such Trigger Event, (b) in connection with a Trigger Event
described in Article 1.7.1(ii)(1) above, within thirty (30) days following the declaration by a
Lender or Administrative Agent (as each such term is defined in the Loan Agreement) of such Trigger
Event, and (c) in connection with a Trigger Event described in Article 1.7.1(ii)(2) above, at any
time prior to, or within thirty (30) days after, such Trigger Event. The closing of the purchase
and sale of the Warrant upon exercise by Holder of the Put Option shall be effected: (x) in
connection with a Trigger Event described in Article 1.7.1(i) above, within 30 days of the closing
thereof, or (y) in connection with a Trigger Event described in Article 1.7.1(ii) above, within 30
days of the determination of fair market value of the Shares. At the closing, the Put Price shall
be paid to Holder by the Company in cash (by certified check or wire transfer of immediately
available funds) in a single installment against delivery of this original Warrant. If less than
all of the Shares evidenced by this Warrant are being purchased at such closing pursuant to
Holder’s exercise of the Put Option, the Company shall also deliver to Holder thereat a new warrant
of like tenor evidencing the Shares as to which the Put Option was not so exercised. In the event
that the Company fails to pay to Holder the full Put Price at the closing of Holder’s exercise of
the Put Option at the time and in the manner required under this Article 1.7, then in addition to
any and all other remedies at law and in equity which Holder has or may have in respect thereof,
the unpaid portion of the Put Price shall bear interest, payable to Holder on demand, at the
Default Rate (as defined in the Loan Agreement), compounded daily, until paid in full.

               1.7.3 Notwithstanding any provision herein to the contrary, the Put Option shall terminate and
be of no further force or effect from and following the consummation of the IPO to the extent not
previously exercised by Holder prior to the consummation of the IPO.

ARTICLE 2. ADJUSTMENTS TO THE SHARES.

          2.1 Stock Dividends, Splits, Etc. If the Company declares or pays a dividend on the
outstanding shares of the Class payable in common stock or other securities, then upon exercise of
this Warrant, for each Share acquired, Holder shall receive, without cost to Holder, the total
number and kind of securities to which Holder would have been entitled had Holder owned the Shares
of record as of the date the dividend occurred. If the Company subdivides the outstanding shares
of the Class by reclassification or otherwise into a greater number of shares, the number of Shares
purchasable hereunder shall be proportionately increased and the Warrant Price shall be
proportionately decreased. If the outstanding shares of the Class are combined or consolidated, by
reclassification or otherwise, into a lesser number of shares, the Warrant Price shall be
proportionately increased and the number of Shares shall be proportionately decreased.

          2.2 Reclassification, Exchange or Substitution.

4

 

               (a) Upon any reclassification, exchange, substitution, or other event affecting the
outstanding shares of the Class, Holder shall be entitled to receive, upon exercise or conversion
of this Warrant, the number and kind of securities and property that Holder would have received for
the Shares if this Warrant had been exercised in full immediately before such reclassification,
exchange, substitution, or other event, at an aggregate Warrant Price not exceeding the aggregate
Warrant Price in effect as of immediately prior thereto. Such an event shall include, without
limitation, any automatic or voluntary conversion of all outstanding shares of the Class to common
stock pursuant to the terms of the Company’s Certificate of Incorporation. The Company or its
successor shall promptly issue to Holder a certificate pursuant to Article 2.8 hereof setting forth
the number, class and series or other designation of such new securities or other property issuable
upon exercise or conversion of this Warrant as a result of such reclassification, exchange,
substitution or other event. The provisions of this Article 2.2 shall similarly apply to
successive reclassifications, exchanges, substitutions, or other events.

               (b) Notwithstanding the foregoing, if all of the outstanding shares of Series B Preferred
Stock of the Company are converted into Common Stock of the Company in accordance with the terms of
the Certificate of Incorporation of the Company, as amended from time to time, then, effective upon
such conversion, (i) this Warrant shall be exercisable for such number of shares of Common Stock as
is equal to the number of shares of Common Stock that each share of Series B Preferred Stock was
converted into, multiplied by the number of shares of Series B Preferred Stock subject to this
Warrant immediately prior to such conversion, (ii) the Warrant Price shall be the Warrant Price in
effect immediately prior to such conversion divided by the number of shares of Common Stock into
which each share of Series B Preferred Stock was converted, and (iii) all references in this
Warrant to “Class,” “Preferred Stock” and “Series B Preferred Stock” shall thereafter be deemed to
refer to “Common Stock” of the Company.

          2.3 Adjustments for Diluting Issuances. The number of shares of common stock
issuable upon conversion of the Shares shall be subject to adjustment, from time to time in the
manner set forth in the Company’s Certificate of Incorporation as if the Shares were issued and
outstanding on and as of the date of any such required adjustment. The provisions set forth for
the Class in the Company’s Certificate of Incorporation relating to the above in effect as of the
Issue Date may not be amended, modified or waived, without the prior written consent of Holder
unless such amendment, modification or waiver affects the rights associated with the Shares in the
same manner as such amendment, modification or waiver affects the rights associated with all other
shares of the Class.

          2.4 Adjustment to Warrant Price on Cash Dividend. At all times prior to the IPO, in
the event that the Company at any time prior or from time to time prior to exercise or conversion
in full of this Warrant pays any cash dividend on the outstanding shares of the Class or makes any
cash distribution on or in respect of the outstanding shares of the Class, then on and as of the
date of such dividend payment or the making of such distribution, the Warrant Price shall be
reduced by an amount equal to the amount paid or distributed upon or in respect of each
outstanding share of the Class.

          2.5 No Impairment. The Company shall not, by amendment of its Certificate of
Incorporation or through a reorganization, transfer of assets, consolidation,

5

 

merger, dissolution, issue, or sale of securities or any other voluntary action, avoid or seek to
avoid the observance or performance of any of the terms to be observed or performed under this
Warrant by the Company, but shall at all times in good faith assist in carrying out of all the
provisions of this Article 2 and in taking all such action as may be both commercially reasonable
and necessary or appropriate to protect Holder’s rights under this Article against impairment.

          2.6 Fractional Shares. No fractional Shares shall be issuable upon exercise or
conversion of the Warrant and the number of Shares to be issued shall be rounded down to the
nearest whole Share. If a fractional share interest arises upon any exercise or conversion of the
Warrant, the Company shall eliminate such fractional share interest by paying Holder the amount
computed by multiplying the fractional interest by the fair market value of a full Share.

          2.7 Pay to Play Adjustments. Notwithstanding the definition of Class herein, if Pay to
Play Provisions are at any time during the term of this Warrant applied to the outstanding shares
of the Class, then from and after such application, “Class” shall mean that class and series of the
Company’s securities that a holder of outstanding shares of the Class as of immediately prior to
such application would have received or retained had such holder participated in the manner
necessary to receive or retain the class and series of the Company’s securities having the relative
rights, powers, privileges and preferences more favorable to the holder. As used herein, “Pay to
Play Provisions” means provisions set forth in the Company’s Certificate of Incorporation or
elsewhere that require holders of the outstanding shares of the Class to participate in a
subsequent round of equity financing of the Company or lose all or a portion of the benefit of
anti-dilution protection or any other right, power, privilege or preference applicable to such
shares or have such shares automatically convert to common stock or another class or series of
Company capital stock.

          2.8 Certificate as to Adjustments. Upon each adjustment of the Warrant Price, Class
and/or number of Shares, the Company shall promptly notify Holder in writing, and, at the Company’s
expense, promptly compute such adjustment, and furnish Holder with a certificate of its Chief
Financial Officer setting forth such adjustment and the facts upon which such adjustment is based.
The Company shall, upon written request, furnish Holder a certificate setting forth the Warrant
Price, Class and number of Shares in effect upon the date thereof and the series of adjustments
leading to such Warrant Price, Class and number of Shares.

ARTICLE 3. REPRESENTATIONS AND COVENANTS OF THE COMPANY.

          3.1 Representations and Warranties. The Company represents and warrants to, and
agrees with, the Holder as follows:

               (a) The initial Warrant Price first set forth above is not greater than the price per share at
which shares of the Class were last issued in an arms-length transaction in which at least $500,000
of such shares were sold.

               (b) All Shares which may be issued upon the exercise of the purchase right represented by this
Warrant, and all securities, if any, issuable upon conversion of the Shares, shall at all time be
duly reserved for issuance out of the authorized and unissued capital stock of the Company and
shall, upon issuance in

6

 

accordance with the provisions hereof, be duly authorized, validly issued, fully paid and
non-assessable, and free of any liens and encumbrances except for restrictions on transfer provided
for herein or under applicable federal and state securities laws.

               (c) The Company’s capitalization table attached hereto as Schedule 1 is true and
complete as of the Issue Date.

          3.2 Notice of Certain Events. If the Company proposes at any time (a) to declare any
dividend or distribution upon the outstanding shares of the Class, whether in cash, property,
stock, or other securities and whether or not a regular cash dividend; (b) to offer for
subscription or sale pro rata to the holders of the outstanding shares of the Class any additional
shares of any class or series of the Company’s stock; (c) to effect any reclassification,
reorganization or recapitalization of the shares of the Class; (d) to effect an Acquisition or to
liquidate, dissolve or wind up; or (e) offer holders of registration rights the opportunity to
participate in an underwritten public offering of the Company’s securities for cash, then, in
connection with each such event, the Company shall give Holder: (1) at least 10 days prior written
notice of the date on which a record will be taken for such dividend, distribution, or subscription
rights (and specifying the date on which the holders of shares of the Class will be entitled
thereto) or for determining rights to vote, if any, in respect of the matters referred to in (c)
and (d) above; (2) in the case of the matters referred to in (c) and (d) above at least 10 days
prior written notice of the date when the same will take place (and specifying the date on which
the holders of shares of the Class will be entitled to exchange their shares for the securities or
other property deliverable upon the occurrence of such event); and (3) in the case of the matter
referred to in (e) above, the same notice as is given to the holders of such registration rights.

          3.3 Registration Under Securities Act of 1933, as amended. The Company agrees that
the Shares or, if the Shares are convertible into common stock of the Company, such common stock,
shall have certain registration rights pursuant to and as set forth in Sections 2.2 through 2.14
inclusive, and 3 (the “Applicable Sections”) of the Company’s Amended and Restated Investor Rights
Agreement, dated July 8, 2008, as amended from time to time (the “Investor Rights Agreement”);
provided, that (1) Holder shall not be permitted to be an Initiating Holder (as defined in
the Investor Rights Agreement) for purposes of making a Demand Request (as defined in the Investor
Rights Agreement) under Section 2.2(a) of the Investor Rights Agreement, and (2) Holder will be
subject to all of the obligations set forth in the Applicable Sections as if Holder were an
original “Holder” (as defined in the Investor Rights Agreement) thereunder. The Applicable
Sections in effect as of the Issue Date may not be amended, modified or waived without the prior
written consent of Holder unless such amendment, modification or waiver affects the rights
associated with the Shares in the same manner as such amendment, modification, or waiver affects
the rights associated with all other shares of the Class whose holders are parties thereto.

          3.4 No Shareholder Rights. Except as provided in this Warrant, Holder will not have
any rights as a shareholder of the Company until the exercise of this Warrant.

          3.5 Certain Information. The Company agrees to provide Holder at any time and from
time to time with such information as Holder may reasonably request

7

 

for purposes of Holder’s compliance with regulatory, accounting and reporting requirements
applicable to Holder.

ARTICLE 4. REPRESENTATIONS, WARRANTIES OF THE HOLDER. The Holder represents and warrants
to the Company as follows:

          4.1 Purchase for Own Account. This Warrant and the securities to be acquired upon
exercise of this Warrant by Holder will be acquired for investment for Holder’s account, not as a
nominee or agent, and not with a view to the public resale or distribution within the meaning of
the Act. Holder also represents that it has not been formed for the specific purpose of acquiring
this Warrant or the Shares.

          4.2 Disclosure of Information. Holder has received or has had full access to all the
information it considers necessary or appropriate to make an informed investment decision with
respect to the acquisition of this Warrant and its underlying securities. Holder further has had
an opportunity to ask questions and receive answers from the Company regarding the terms and
conditions of the offering of this Warrant and its underlying securities and to obtain additional
information (to the extent the Company possessed such information or could acquire it without
unreasonable effort or expense) necessary to verify any information furnished to Holder or to which
Holder has access.

          4.3 Investment Experience. Holder understands that the purchase of this Warrant and
its underlying securities involves substantial risk. Holder has experience as an investor in
securities of companies in the development stage and acknowledges that Holder can bear the economic
risk of such Holder’s investment in this Warrant and its underlying securities and has such
knowledge and experience in financial or business matters that Holder is capable of evaluating the
merits and risks of its investment in this Warrant and its underlying securities and/or has a
preexisting personal or business relationship with the Company and certain of its officers,
directors or controlling persons of a nature and duration that enables Holder to be aware of the
character, business acumen and financial circumstances of such persons.

          4.4 Accredited Investor Status. Holder is an “accredited investor” within the meaning
of Regulation D promulgated under the Act.

          4.5 The Act. Holder understands that this Warrant and the Shares issuable upon
exercise or conversion hereof have not been registered under the Act in reliance upon a specific
exemption therefrom, which exemption depends upon, among other things, the bona fide nature of the
Holder’s investment intent as expressed herein. Holder understands that this Warrant and the
Shares issued upon any exercise or conversion hereof must be held indefinitely unless subsequently
registered under the Act and qualified under applicable state securities laws, or unless exemption
from such registration and qualification are otherwise available.

          4.6 Market “Stand-Off” Agreement. Holder agrees to comply with and be bound by the
provisions of Section 2.13 of the Investor Rights Agreement to the same extent as all other holders
of shares of the Class are bound thereby.

ARTICLE 5. MISCELLANEOUS.

8

 

          5.1 Term: This Warrant is exercisable in whole or in part at any time and from time
to time on or before the Expiration Date.

          5.2 Legends. This Warrant and the Shares (and the securities issuable, directly or
indirectly, upon conversion of the Shares, if any) shall be imprinted with a legend in
substantially the following form:

THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED
UNDER THE ACT, OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AND
PURSUANT TO THE PROVISIONS OF ARTICLE 5 OF THAT CERTAIN WARRANT TO
PURCHASE STOCK ISSUED BY THE COMPANY TO SILICON VALLEY BANK DATED AS OF
MAY 13, 2010, MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED
OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND APPLICABLE
STATE SECURITIES LAW OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND
SUBSTANCE SATISFACTORY TO THE ISSUER OF THESE SECURITIES, SUCH OFFER, SALE
OR TRANSFER, PLEDGE OR HYPOTHECATION IS EXEMPT FROM REGISTRATION.

          5.3 Compliance with Securities Laws on Transfer. This Warrant and the Shares issuable
upon exercise of this Warrant (and the securities issuable, directly or indirectly, upon conversion
of the Shares, if any) may not be transferred or assigned in whole or in part without compliance
with applicable federal and state securities laws by the transferor and the transferee (including,
without limitation, the delivery of investment representation letters and legal opinions reasonably
satisfactory to the Company, as reasonably requested by the Company). The Company shall not
require Holder to provide an opinion of counsel if the transfer is to any affiliate of Holder,
provided that any such affiliate transferee is an “accredited investor” as defined in Regulation D
promulgated under the Act.

          5.4 Transfer Procedure. After receipt by Silicon Valley Bank (“Bank”) of
the executed Warrant, Bank will transfer all of this Warrant to SVB Financial Group, Holder’s
parent company. Subject to the provisions of Article 5.3 and upon providing the Company with
written notice, SVB Financial Group and any subsequent Holder may transfer all or part of this
Warrant or the Shares issuable upon exercise of this Warrant (or the securities issuable directly
or indirectly, upon conversion of the Shares, if any) to any transferee, provided, however, in
connection with any such transfer, SVB Financial Group or any subsequent Holder will give the
Company notice of the portion of the Warrant being transferred with the name, address and taxpayer
identification number of the transferee and Holder will surrender this Warrant to the Company for
reissuance to the transferee(s) (and Holder if applicable). The Company may refuse to transfer
this Warrant or the Shares to any person who (i) directly competes with the Company, unless, in
either case, the stock of the Company is publicly traded or (ii) fails to agree in writing to agree
to be bound by the terms of this Warrant as if an original holder hereof.

          5.5 Notices. All notices and other communications from the Company to the Holder, or
vice versa, shall be deemed delivered and effective when given personally or mailed by first-class
registered or certified mail, postage prepaid (or on the

9

 

first business day after transmission by facsimile), at such address as may have been furnished to
the Company or Holder, as the case may be, in writing by the Company or such holder from time to
time. All notices to Holder shall be addressed as follows until the Company receives notice of a
change of address in connection with a transfer or otherwise:

SVB Financial Group

Attn: Treasury Department

3003 Tasman Drive, HA 200

Santa Clara, CA 95054

Telephone: 408-654-7400

Facsimile: 408-496-2405

     Notice to the Company shall be addressed as follows until Holder receives notice of a change
in address:

NuPathe, Inc.

Attn: Keith A. Goldan

227 Washington Street, Suite 200

Conshohocken, Pennsylvania 19428

Telephone: 484.567.0130

Facsimile: 484.567.0136

          5.6 Waiver. This Warrant and any term hereof may be changed, waived, discharged or
terminated only by an instrument in writing signed by the party against which enforcement of such
change, waiver, discharge or termination is sought.

          5.7 Attorney’s Fees. In the event of any dispute between the parties concerning the
terms and provisions of this Warrant, the party prevailing in such dispute shall be entitled to
collect from the other party all costs incurred in such dispute, including reasonable attorneys’
fees.

          5.8 Automatic Conversion upon Expiration. In the event that, upon the Expiration
Date, the fair market value of one Share (or other security issuable upon the exercise hereof) as
determined in accordance with Article 1.3 above is greater than the Warrant Price in effect on such
date, then this Warrant shall automatically be deemed on and as of such date to be converted
pursuant to Article 1.2 above as to all Shares (or such other securities) for which it shall not
previously have been exercised or converted, and the Company shall promptly deliver a certificate
representing the Shares (or such other securities) issued upon such conversion to Holder.

          5.9 Counterparts. This Warrant may be executed in counterparts, all of which together
shall constitute one and the same agreement.

          5.10 Governing Law. This Warrant shall be governed by and construed in accordance
with: (i) to the extent applicable, the General Corporation Law of the State of Delaware, and (ii)
otherwise, the internal domestic laws of the State of Maryland, without giving effect to its
principles regarding conflicts of law.

[Remainder of page left blank intentionally; signature page follows]

10

 

     IN WITNESS WHEREOF, the parties hereto have caused this Warrant to Purchase Stock to be duly
executed as of the date first set forth above.

	 	 	 	 	 
	
“COMPANY” 

NUPATHE, INC. 

 	 	 
	By:  	/s/  Keith A. Goldan
 	 	 
	 	Name:  	Keith A. Goldan
(Print) 	 	 
	 	Title:  	
CFO 	 	 
	 
	“HOLDER” 

SILICON VALLEY BANK 

 	 	 
	By:  	/s/  Thomas F. Gordon
 	 	 
	 	Name:  	Thomas F. Gordon
(Print) 	 	 
	 	Title:  	
Senior Vice President 	 	 

11

 

APPENDIX 1

NOTICE OF EXERCISE

     1. Holder elects to purchase _________ shares of the Common/Series _________ Preferred [strike
one] Stock of _________ pursuant to the terms of the attached Warrant, and tenders payment
of the purchase price of the shares in full.

          [or]

     1. Holder elects to convert the attached Warrant into Shares/cash [strike one] in the manner
specified in the Warrant. This conversion is exercised for ____________ of the Shares
covered by the Warrant.

     [Strike paragraph that does not apply.]

     2. Please issue a certificate or certificates representing the Shares in the name specified
below:

	 	 	 	 	 

	 
	 

	 	Holders Name	 	 
	 
	 
	 

	 	 	 	 
	 
	 

	 	(Address)	 	 

     3. By its execution below and for the benefit of the Company, Holder hereby restates each of
the representations and warranties in Article 4 of the Warrant as of the date hereof.

	 	 	 	 	 
	 	HOLDER:

 	 
	 	
By:  	 	 
	 	 	Name: 	 	 
	 	 	Title: 	 	 
	 	 	(Date): 	 	 

12

 

	 	 	 	 	 

SCHEDULE 1

Company Capitalization Table

See attached

13exv10w1

Exhibit 10.1

Confidential

Confidential treatment requested under 17 C.F.R. §§ 200.80(b)(4) and 230.406. The
confidential portions of this exhibit have been omitted and are marked accordingly. The
confidential portions have been filed separately with the Securities and Exchange Commission
pursuant to the Confidential Treatment Request.

University of Pennsylvania

Patent License Agreement

This Patent License Agreement (this “Agreement”) is between The Trustees of the University of
Pennsylvania, a Pennsylvania nonprofit corporation (“Penn”), and NuPathe Inc., a corporation
organized and existing under the laws of Delaware, (“Company”). This Agreement is being signed on
June 21, 2006 (the “Execution Date”). This Agreement will become effective on July 1, 2006 (the
“Effective Date”).

BACKGROUND

Penn owns certain intellectual property developed by Dr. Steve Siegel of Penn’s School of Medicine
relating to surgically implantable drug delivery systems. Penn also owns certain letters patent
and/or applications for letters patent relating to the intellectual property. Company desires to
obtain an exclusive license under the patent rights to exploit the intellectual property. Company
also desires to fund further research by Dr. Steve Siegel under a separate agreement. Penn has
determined that the exploitation of the intellectual property by Company is in the best interest of
Penn and is consistent with its educational and research missions and goals.

In consideration of the mutual obligations contained in this Agreement, and intending to be legally
bound, the parties agree as follows:

	1.	 	LICENSE

     1.1 License Grant. Penn grants to Company an exclusive, world-wide license (the
“License”) to make, have made, use, import, offer for sale and sell Licensed Products in the Field
of Use during the Term (as such terms may be defined in Sections 1.2 and 6.1). The License includes
the right to sublicense as permitted by this Agreement. No other rights or licenses are granted by
Penn. Any intellectual property created or conceived during the performance of the Sponsored
Research Agreement between Penn and Company being entered into simultaneously with this Agreement
(the “Sponsored Research Agreement”) will be governed solely by the terms of the Sponsored Research
Agreement.

     1.2 Definitions. The term “Licensed Products” means products that are made, made for,
used, imported, offered for sale or sold by Company or its Affiliates or sublicensees and that
either (i) in the absence of this Agreement, would infringe at least one claim of the Patent Rights
or (ii) use a process or machine covered by a claim of Patent Rights, in either case whether or not
the claim is issued or pending. The term “Patent Rights” means all patent rights represented by or
issuing from: (a) the United States patents and patent applications listed in Exhibit A; (b) any
continuation, divisional, re-examinations and re-issue applications of (a); and (c) any foreign
counterparts and extensions of (a) or (b). The term “Field of Use” means all fields. The term
“Platform Technology” means an implantable biodegradable drug delivery system which is covered by
one or more claims of the Patent Rights. The term “Active Ingredient” means an active
pharmaceutical ingredient for the prevention and/or treatment of human and veterinary conditions
and diseases. The term “Affiliate” means a legal entity that is controlling, controlled by or under
common control with Company and that has executed either this Agreement or a

1

 

Confidential

written Joinder Agreement agreeing to be bound by all of the terms and conditions of this
Agreement. For purposes of this Section 1.2, the word “control” means (x) the direct or indirect
ownership of more than fifty percent (50%) of the outstanding voting securities of a legal entity,
(y) the right to receive fifty percent (50%) or more of the profits or earnings of a legal entity,
or (z) the right to determine the policy decisions of a legal entity. The term “Commercially
Reasonable Efforts” means with respect to a party, the efforts and resources which would be used by
that party relating to a certain activity or activities which are consistent with the general level
of effort and resources in the pharmaceutical industry for a company similar in size and scope.

     1.3 Reservation of Rights by Penn. Penn reserves the right to use, and to permit
other non-commercial entities to use, the Patent Rights for educational and research purposes.

     1.4 U.S. Government Rights. The parties acknowledge that the United States government
retains rights in intellectual property funded under any grant or similar contract with a Federal
agency. The License is expressly subject to all applicable United States government rights,
including, but not limited to, any applicable requirement that products, which result from such
intellectual property and are sold in the United States, must be substantially manufactured in the
United States.

     1.5 Sublicense Conditions. The Company’s right to sublicense granted by Penn under
the License is subject to each of the following conditions:

          (a) [**].

          (b) Within thirty (30) days after Company enters into a sublicense agreement, Company will
deliver to Penn a complete and accurate copy of the entire sublicense agreement written in the
English language. Penn’s receipt of the sublicense agreement, however, will constitute neither an
approval of the sublicense nor a waiver of any right of Penn or obligation of Company under this
Agreement.

          (c) [**].

          (d) Company’s execution of a sublicense agreement will not relieve Company of any of its
obligations under this Agreement. Company is primarily liable to Penn for any act or omission of an
Affiliate or sublicensee of Company that would be a breach of this Agreement if performed or
omitted by Company.

     1.6 Option Grant. During an eighteen month period after the Effective Date, Company
will have an exclusive option (each, an “Option”) to negotiate an exclusive license for any new
patent rights that (i) arise out of any improvement or modification of the Platform Technology that
is not already covered by the Penn Patent Rights, (ii) are in Penn’s full control (not arising from
research funded by any commercial entities or funded by the Company under the Sponsored Research
Agreement), and (iii) are developed or discovered by or under direction of or in the laboratory of
Dr. Steve Siegel at Penn (an “Improvement”). Penn shall promptly notify Company in writing of any
Improvement and if Company desires a license to any such

 

			
	**	 	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

2

 

Confidential

Improvement , then Company shall so advise Penn in writing within thirty (30) days of receipt
of such notice, and Company and Penn shall negotiate the terms of a license amendment therefore in
good faith under commercially reasonable terms within seven (7) months of date of disclosure to
Company, after which time Penn is free to license such Improvement to third parties with no further
obligation to Company.

	2.	 	DILIGENCE

     2.1 Development Plan. Company will deliver to Penn, within ninety (90) days after the
Effective Date, a copy of an initial development plan for the Patent Rights (the “Development
Plan”). The purpose of the Development Plan is (a) to demonstrate Company’s capability to bring the
Patent Rights to commercialization, (b) to project the timeline for completing the necessary tasks,
and (c) to measure Company’s progress against the projections. Thereafter, Company will deliver to
Penn an annual updated Development Plan no later than December 1 of each year during the Term. The
Development Plan will include, at a minimum, milestones for initiation of animal testing;
initiation of formal preclinical studies; initiation of human clinical trials; initiation of Phase
II clinical trials; and commercial launch, additional information as listed in Exhibit B, and shall
be approved by Penn.

     2.2 Company’s Efforts. Company will use Commercially Reasonable Efforts to develop,
commercialize, market and sell Licensed Products in a manner consistent with the Development Plan.

     2.3 Development Expenditures. Until the first commercial sale of the first Licensed
Product, Company will commit financial resources to the development and commercialization of
Licensed Products in amounts not less than specified in the table below (“Development
Expenditures”) in each 12-month period following the Effective Date. [**].

	 	 	 	 	 

	Year 1
	 	$	[**]	 
	Year 2
	 	$	[**]	 
	Year 3
	 	$	[**]	 
	All years thereafter
	 	$	250,000	 

[**]

 

			
	**	 	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

3

 

Confidential

	3.	 	FEES AND ROYALTIES

     3.1 License Initiation Fee. In partial consideration of the License, Company will pay
to Penn on the Effective Date a non-refundable, non-creditable license initiation fee of $[**].

     3.2 License Maintenance Fees. In partial consideration of the License, Company will
pay to Penn, on each anniversary of the Effective Date until the first Sale (as defined in Section
3.5) of the first Licensed Product, the applicable license maintenance fee listed in the table
below.

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	First and	 	 	 	 	 	 	 	 	 	Fifth and
	ANNIVERSARY:	 	Second	 	Third	 	Fourth	 	thereafter
	LICENSE MAINTENANCE FEE:
	 	$	[**]	 	 	$	[**]	 	 	$	30,000	 	 	$	50,000	 

     3.3 Milestone Payments. In partial consideration of the License, Company will pay to
Penn the applicable Total Milestone payment listed in the table below within forty-five (45) days
after the end of the calendar quarter during which each milestone event for each Licensed Product
is achieved, according to the following table. Each Total Milestone shall be payable once per
Active Ingredient. Company will provide Penn with written notice within thirty (30) days after
achieving each milestone.

	 	 	 	 	 	 	 
	 	 	Platform	 	Active. Ingredient	 	Total Milestone Payment
	Milestone	 	Payment	 	Multiplier	 	=Platform Payment (Y)
	[**]
	 	$[**]	 	Y	 	$[**]
	[**]
	 	$[**]	 	Y	 	$[**]
	[**]
	 	$[**]	 	Y	 	$[**]
	[**]
	 	$[**]	 	Y	 	$[**]

For Penn Licensed Products that include an active ingredient that is risperidone and/or
haloperidol, the Active Ingredient Multiplier =[**]. For clarity, the milestone payments for Penn
Licensed Products that include an active ingredient that is risperidone and/or haloperidol the
Total Milestone Payments are:

	 	 	 

	[**]

	 	$[**]
	[**]

	 	$[**]
	[**]

	 	$[**]
	[**]

	 	$[**]

     3.4 Earned Royalties. In partial consideration of the License, within forty-five (45)
days after the end of each calendar quarter, Company will pay to Penn a Total Royalty of

 

			
	**	 	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

4

 

Confidential

worldwide Net Sales of Penn Licensed Products during the Quarter according to the table below
and deliver to Penn a report detailing Net Sales for the quarter:

	 	 	 	 	 
	Platform Royalty (%)	 	Active Ingredient Royalty Multiplier	 	Total Royalty (%)
	[**]

	 	X
	 	[**](X)

Royalties shall be payable on a product-by-product basis until the end of the Term. Under no
circumstances shall the Active Ingredient Royalty Multiplier be less than [**] for any Penn
Licensed Products . [**].

For Penn Licensed Products that include an Active Ingredient that is risperidone and/or
haloperidol, the Royalty Multiplier =[**]. For clarity, for Penn Licensed Products that include an
Active Ingredient that is risperidone and/or haloperidol, the Total Royalty is [**]%.

     3.5 Related Definitions. The term “Sale” means any bona fide transaction for which
consideration is received or expected by Company or its Affiliate or sublicensee for the sale, use,
lease, transfer or other disposition of a Licensed Product to a third party. A Sale is deemed
completed at the time that Company or its Affiliate or sublicensee invoices, ships or receives
payment for a Licensed Product, whichever occurs first. The term “Quarter” means each three-month
period beginning on January 1, April 1, July 1 and October 1. The term “Net Sales” means the
consideration received or expected from, or the fair market value attributable to, each Sale, less
Qualifying Costs that are directly attributable to a Sale, specifically identified on an invoice or
other documentation and actually borne by Company or its Affiliates or sublicensees. For purposes
of determining Net Sales, the words “fair market value” mean the cash consideration that Company or
its Affiliates or sublicensees would realize from an unrelated buyer in an arms length sale of an
identical item sold in the same quantity and at the time and place of the transaction. The term
“Qualifying Costs” means: (a) returned goods;(b) trade and quantity discounts; (c) rebates; (d)
payments in respect of any governmental subsidized program; (e) reimbursement or similar payments
given to wholesalers or other distributors, buying groups, healthcare insurance carriers or other
institutions; (f) sales or other taxes actually paid by Company or its sub-licensees, not including
taxes assessed on the income resulting from such sales; and (g) freight allowances, insurance and
customs duties to the extent any of the foregoing are identified on the invoice for the Licensed
Product.

     3.6 Sublicense Fees. In partial consideration of the License, within 45 days after
the end of each calendar quarter after the Effective Date, Company will pay to Penn a sublicense
fee of the applicable percentage listed in the table below of [**].

	 	 	 

	[**]
	 	[**]%
	[**]
	 	[**]%
	[**]
	 	[**]%

     3.7 Transaction Fee. In partial consideration of the License, Company will pay to
Penn, within thirty (30) days after the Execution Date, a one-time, non-refundable, non-creditable
transaction fee of $[**] with respect to Penn’s licensing and legal expenses in

 

			
	**	 	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

5

 

Confidential

connection with this Agreement and the Term Sheet between the parties dated April 7, 2006 (the
“Term Sheet”).

	4.	 	REPORTS AND PAYMENTS

     4.1 Royalty Reports. Within forty-five (45) days after the end of each Quarter
following the first Sale, Company will deliver to Penn a report, certified by the chief financial
officer of Company, detailing the calculation of all royalties, fees and other payments due to Penn
for such Quarter. The report will include, at a minimum, the following information for the Quarter,
each listed by product, by country: (a) the number of units of Licensed Products constituting
Sales; (b) the gross consideration invoiced, billed or received for Sales; (c) Qualifying Costs,
listed by category of cost; (d) Net Sales; (e) the gross amount of any payments and other
consideration received by Company from sublicensees and the amounts of any deductions permitted by
Section 3.6; (f) the royalties, fees and other payments owed to Penn, listed by category; and (g)
the computations for any applicable currency conversions. Each royalty report will be substantially
in the form of the sample report attached as Exhibit C.

     4.2 Payments. Company will pay all royalties, fees and other payments due to Penn
under Sections 3.3, 3.4, and 3.6 within forty-five (45) days after the end of the Quarter in which
the royalties, fees or other payments accrued.

     4.3 Records. Company will maintain, and will cause its Affiliates and sublicensees to
maintain, complete and accurate books, records and related background information to verify Sales,
Net Sales, and all of the royalties, fees, and other payments due or paid under this Agreement, as
well as the various computations reported under Section 4.1. The records for each Quarter will be
maintained for at least five (5) years after submission of the applicable report required under
Section 4.1.

     4.4 Audit Rights. Upon reasonable prior written notice to Company, Company and its
Affiliates and sublicensees will provide Penn and its accountants with access to all of the books,
records and related background information required by Section 4.3 to conduct a review or audit of
Sales, Net Sales, and all of the royalties, fees, and other payments payable under this Agreement.
Access will be made available: (a) during normal business hours; (b) in a manner reasonably
designed to facilitate Penn’s review or audit without unreasonable disruption to Company’s
business; and (c) no more than once each calendar year during the Term (as defined below) and for a
period of five (5) years thereafter. Company will promptly pay to Penn the amount of any
underpayment determined by the review or audit, plus accrued interest. If the review or audit
determines that Company has underpaid any payment by five percent (5%) or more, then Company will
also promptly pay the costs and expenses of Penn and its accountants in connection with the review
or audit. In addition, once annual Sales of Licensed Products exceed [**] ($[**]), Company will
conduct, at least once every two (2) years at its own expense, an independent audit of Sales, Net
Sales, and all of the royalties, fees, and other payments due or paid under this Agreement.
Promptly after completion of the audit, Company will provide to Penn a copy of the report of the
independent auditors.

 

			
	**	 	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

6

 

Confidential

     4.5 Information Rights. Until the closing of the Company’s initial public offering,
Company will provide to Penn the relevant sections of financial information, business plans and
management reports related to the Licensed Products and prepared for and distributed to its
investors or other stockholders, approximately on a bi-annual basis. If, and at such time, as the
Company completes an initial public offering, Company will provide to Penn, promptly after filing,
a copy of each annual report, proxy statement, 10-K, 10-Q and other material report filed with the
U.S. Securities and Exchange Commission.

     4.6 Currency. All dollar amounts referred to in this Agreement are expressed in
United States dollars. All payments will be made in United States dollars. If Company receives
payment from a third party in a currency other than United States dollars for which a royalty or
fee is owed under this Agreement, then (a) the payment will be converted into United States dollars
at the conversion rate for the foreign currency as published in the eastern edition of the Wall
Street Journal as of the last business day of the Quarter in which the payment was received by
Company, and (b) the conversion computation will be documented by Company in the applicable report
delivered to Penn under Section 4.1.

     4.7 Place of Payment. All payments by Company are payable to “The Trustees of the
University of Pennsylvania” and will be made to the following addresses:

	 	 	 	 	 	 
	 	 	By Electronic Transfer:	 	By Check:	
	 

	 	Mellon Bank East
	 	The Trustees of the University of Pennsylvania	
	 

	 	ABA #031000037
	 	c/o Center for Technology Transfer	
	 

	 	Account Number: 2945020
	 	P.O. Box 7777-W3850	
	 

	 	c/o: CTT / T. Dunn
	 	Philadelphia, PA 19175-3850	

     4.8 Interest. All amounts that are not paid by Company when due will accrue interest
from the date due until paid at a rate equal to one and one-half percent (1.5%) per month (or the
maximum allowed by law, if less).

	5.	 	CONFIDENTIALITY AND USE OF PENN’S NAME

     5.1 Confidentiality Agreement. If Company and Penn entered into one or more
Confidential Disclosure Agreements prior to the Effective Date, then such agreements will continue
to govern the protection of confidential information under this Agreement, and each Affiliate and
sublicensee of Company will be bound to Company’s obligations under such agreements. If, however,
no Confidential Disclosure Agreement has been entered into between Company and Penn prior to the
Effective Date, then in connection with the execution of this Agreement, the parties will enter
into a Confidential Disclosure Agreement substantially similar to Penn’s standard form. The term
"Confidentiality Agreement” means all Confidential Disclosure Agreements between the parties that
remain in effect after the Effective Date.

     5.2 Other Confidential Matters. Penn is not obligated to accept any confidential
information from Company, except for the documents and/or reports required by Sections 1.5(b), 2.1,
4.1, 4.4 and 6.6. Penn, acting through its Center for Technology Transfer and finance offices,
will use reasonable efforts not to disclose to any third party outside of Penn any

7

 

Confidential

confidential information of Company contained in those reports, for so long as such information
remains confidential. Penn bears no institutional responsibility for maintaining the
confidentiality of any other information of Company. Company may elect to enter into
confidentiality agreements with individual investigators at Penn that comply with Penn’s internal
policies.

     5.3 Use of Penn’s Name. Company and its Affiliates, sublicensees, employees, and
agents may not use the name, logo, seal, trademark, or service mark (including any adaptation of
them) of Penn or any Penn school, organization, employee, student or representative, without the
prior written consent of Penn.

	6.	 	TERM AND TERMINATION

     6.1 Term. This Agreement will commence on Effective Date and terminate upon the later
of: (a) the expiration or abandonment of the last patent to expire or become abandoned of the
Patent Rights; or (b) ten (10) years after the first Sale of the first Licensed Product if no
patent has issued from the Patent Rights (as the case may be, the “Term”).

     6.2 Early Termination by Company. Company may terminate this Agreement at any time
effective upon completion of each of the following conditions: (a) providing at least sixty (60)
days prior written notice to Penn of such intention to terminate; (b) ceasing to make, have made,
use, import, offer for sale and sell all Licensed Products; (c) terminating all sublicenses and
causing all Affiliates and sublicensees to cease making, having made, using, importing, offering
for sale and selling all Licensed Products; and (d) paying all amounts owed to Penn under this
Agreement and the Sponsored Research Agreement through the effective date of termination.

     6.3 Early Termination by Penn. Penn may terminate this Agreement if: (a) Company is
more than thirty (30) days late in paying to Penn any amounts owed under this Agreement and does
not immediately pay Penn in full, including accrued interest, upon demand; (b) Company or its
Affiliate or sublicensee breaches this Agreement and does not cure the breach within forty five
(45) days after written notice of the breach; or (c) Company or its Affiliate experiences a Trigger
Event.

     6.4 Trigger Event. The term “Trigger Event” means any of the following: (a) a
material default by Company under this Agreement that is not cured during any specified cure
periods; (b) if Company or its Affiliate (i) becomes insolvent, bankrupt or generally fails to pay
its debts as such debts become due, (ii) is adjudicated insolvent or bankrupt, (iii) admits in
writing its inability to pay its debts, (iv) suffers the appointment of a custodian, receiver or
trustee for it or its property and, if appointed without its consent, not discharged within thirty
(30) days, (v) makes an assignment for the benefit of creditors, or (iv) suffers proceedings being
instituted against it under any law related to bankruptcy, insolvency, liquidation or the
reorganization, readjustment or release of debtors and, if contested by it, not dismissed or stayed
within ten (10) days; (c) the institution or commencement by Company or its Affiliate of any
proceeding under any law related to bankruptcy, insolvency, liquidation or the reorganization,
readjustment or release of debtors; (d) the entering of any order for relief relating to any of the
proceedings described in Section 6.4(b) or (c) above; or (e) the calling by Company or its

8

 

Confidential

Affiliate of a meeting of its creditors with a view to arranging a composition or adjustment
of its debts; or (f) the act or failure to act by Company or its Affiliate indicating its consent
to, approval of or acquiescence in any of the proceedings described in Section 6.4(b) — (e) above.

     6.5 Effect of Termination. Upon the termination of this Agreement for any reason: (a)
the License terminates; (b) Company and all its Affiliates and sublicensees will cease all making,
having made, using, importing, offering for sale and selling all Licensed Products, except to
extent permitted by Section 6.6; (c) Company will pay to Penn all amounts, including accrued
interest, owed to Penn under this Agreement through the date of termination; (d) Company will, at
Penn’s request, return to Penn all confidential information of Penn and provide to Penn one
complete copy of all data with respect to Licensed Products generated by Company during the Term
that will facilitate the further development of the technology licensed under this Agreement; and
(e) in the case of termination under Section 6.3, all duties of Penn and all rights (but not
duties) of Company under this Agreement immediately terminate without further action required by
either Penn or Company.

     6.6 Inventory & Sell Off. Upon the termination of this Agreement for any reason,
Company will cause physical inventories to be taken immediately of: (a) all completed Licensed
Products on hand under the control of Company or its Affiliates or sublicensees; and (b) such
Licensed Products as are in the process of manufacture and any component parts on the date of
termination of this Agreement. Company will deliver promptly to Penn a copy of the written
inventory, certified by an officer of the Company. Upon termination of this Agreement for any
reason, Company will promptly remove, efface or destroy all references to Penn from any
advertising, labels, web sites or other materials used in the promotion of the business of Company
or its Affiliates or sublicensees, and Company and its Affiliates and sublicensees will not
represent in any manner that it has rights in or to the Patent Rights or the Licensed Products.
Upon the termination of this Agreement for any reason other than pursuant to Section 6.3(a) or (c),
Company may sell off its inventory of Licensed Products existing on the date of termination for a
period of six (6) months and pay Penn royalties on Sales of such inventory within thirty (30) days
following the expiration of such six (6) month period.

     6.7 Survival. Company’s obligation to pay all amounts, including accrued interest,
owed to Penn under this Agreement will survive the termination of this Agreement for any reason.
Sections 13.10 and 13.11 and Articles 4, 5, 6, 9, 10, and 11 will survive the termination of this
Agreement for any reason in accordance with their respective terms.

9

 

Confidential

	7.	 	PATENT MAINTENANCE AND REIMBURSEMENT

     7.1 Patent Maintenance. Penn controls the preparation, prosecution and maintenance of
the Patent Rights and the selection of patent counsel, with input from Company. If, however,
Company desires to manage the preparation, prosecution and maintenance of the Patent Rights with
input from Penn, then Company and Penn will enter into with patent counsel a Patent Management
Agreement in the form attached as Exhibit D.

     7.2 Patent Reimbursement. Within thirty (30) days after the Effective Date, Company
will reimburse Penn for all historically accrued attorneys fees, expenses, official fees and all
other charges accumulated prior to the Effective Date incident to the preparation, filing,
prosecution and maintenance of the Patent Rights, including any interference negotiations, claims
or proceedings. Thereafter, Company will either pay directly under the Patent Management Agreement
or reimburse Penn for all documented attorneys fees, expenses, official fees and all other charges
accumulated on or after the Effective Date incident to the preparation, filing, prosecution, and
maintenance of the Patent Rights, including any interference negotiations, claims or proceedings,
within thirty (30) days after Company’s receipt of invoices for such fees, expenses and charges.

	8.	 	INFRINGEMENT

     8.1 Notice. Company and Penn will notify each other promptly of any infringement of
the Patent Rights that may come to their attention. Company and Penn will consult each other in a
timely manner concerning any appropriate response to the infringement.

     8.2 Prosecution. Company may prosecute any infringement of the Patent Rights at
Company’s expense. Company must not settle or compromise any such litigation in a manner that
imposes any obligations or restrictions on Penn or grants any rights to the Patent Rights without
Penn’s prior written permission. Financial recoveries from any such litigation will be: (a) first,
applied to reimburse Company for its litigation expenditures; and (b) second, as to any remainder,
retained by Company but treated (as appropriate) as either (i) Net Sales for the purpose of
determining the royalties due to Penn under Section 3.4 or (ii) sublicense consideration for the
purpose of determining the sublicense fees due to Penn under Section 3.6.

     8.3 Intervention.

          (a) Voluntary Intervention. Penn reserves the right to voluntarily intervene and join
Company in any litigation under Section 8.2. If Penn voluntarily elects to participate in any such
litigation, then financial recoveries from any such litigation will be shared between Company and
Penn as follows: (1) on a pro rata basis in proportion with their respective shares of the
aggregate Litigation Expenditures by Company and Penn, until the party that spent a lower amount on
its Litigation Expenditures has recovered all of its Litigation Expenditures; then (2) any amounts
remaining shall be paid to the other party to this Agreement, until that party has recovered all of
its Litigation Expenditures; and then (3) [**] percent ([**]%) of any amount remaining would be
paid to Penn, and [**] percent ([**]%) of any amount remaining would be paid to Company, regardless
of respective Litigation Expenditures. For purposes of this

 

			
	**	 	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

10

 

Confidential

Agreement, “Litigation Expenditures” shall be defined as: reasonable attorneys’ fees, court
costs, local counsel fees, deposition costs, subpoena costs, court reporter costs, expert fees, and
other reasonable expenses directly incurred for investigation or litigation of claims.

     (b) Involuntary Participation. If Penn is required to participate involuntarily in
any litigation referred to under Section 8.2, (such as, for example, but not limited to, being
joined or named as a defendant, necessary party, involuntary plaintiff, or indispensable party),
then (i) Company will reimburse Penn’s Litigation Expenditures on an ongoing basis, within 30 days
of submission of actual invoices; and (ii) financial recoveries from any such litigation will be
shared between Company and Penn as follows: (1) Company will be reimbursed for all Litigation
Expenditures of Company and Litigation Expenses reimbursed by Company to Penn; then (2) [**]
percent ([**]%) of any amount remaining would be paid to Penn, and [**] percent ([**]%) of any
amount remaining would be paid to Company, regardless of respective Litigation Expenditures.

     8.4 Penn Prosecution. If Company does not prosecute any infringement of the Patent
Rights, then Penn may elect to prosecute such infringement at Penn’s expense. If Penn elects to
prosecute such infringement, then any financial recoveries will retained by Penn in their entirety.

     8.5 Cooperation. In any litigation under this Article 8, either party, at the request
and expense of the other party, will cooperate to the fullest extent reasonably possible. This
Section 8.5 will not be construed to require either party to undertake any activities, including
legal discovery, at the request of any third party, except as may be required by lawful process of
a court of competent jurisdiction.

	9.	 	DISCLAIMER OF WARRANTIES

     9.1 Disclaimer. THE PENN PATENT RIGHTS, LICENSED PRODUCTS AND ANY OTHER TECHNOLOGY
LICENSED UNDER THIS AGREEMENT ARE PROVIDED ON AN “AS IS” BASIS. PENN MAKES NO REPRESENTATIONS OR
WARRANTIES, EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO ANY WARRANTY OF ACCURACY,
COMPLETENESS, PERFORMANCE, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, COMMERCIAL UTILITY,
NON-INFRINGEMENT OR TITLE.

	10.	 	LIMITATION OF LIABILITY

     10.1 Limitation of Liability. PENN WILL NOT BE LIABLE TO COMPANY, ITS AFFILIATES,
SUBLICENSEES, SUCCESSORS OR ASSIGNS WITH RESPECT TO ANY CLAIM: ARISING FROM COMPANY’S USE OF THE
PENN PATENT RIGHTS, LICENSED PRODUCTS OR ANY OTHER TECHNOLOGY LICENSED UNDER THIS AGREEMENT;
ARISING FROM THE DEVELOPMENT, TESTING, MANUFACTURE, USE OR SALE OF LICENSED PRODUCTS; OR FOR LOST
PROFITS, BUSINESS INTERRUPTION, OR INDIRECT, SPECIAL OR CONSEQUENTIAL DAMAGES OF ANY KIND. IN
ADDITON, IN NO EVENT SHALL COMPANY BE LIABLE TO PENN FOR INDIRECT, SPECIAL OR CONSEQUENTIAL DAMAGES
OF ANY KIND.

 

			
	**	 	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

11

 

Confidential

	11.	 	INDEMNIFICATION

     11.1 Indemnification. Company will defend, indemnify, and hold harmless each
Indemnified Party from and against any and all Liabilities with respect to an Indemnification
Event. The term “Indemnified Party” means each of Penn and its trustees, officers, faculty, agents,
contractors, employees and students. The term “Liabilities” means all damages, awards,
deficiencies, settlement amounts, defaults, assessments, fines, dues, penalties, costs, fees,
liabilities, obligations, liens, losses, and expenses (including, but not limited to, court costs,
interest and reasonable fees of attorneys, accountants and other experts) that are incurred by an
Indemnified Party or awarded or otherwise required to be paid to third parties by an Indemnified
Party. The term “Indemnification Event” means any Claim against one or more Indemnified Parties
arising out of or resulting from: (a) the development, testing, use, manufacture, promotion, sale
or other disposition of any Penn Patent Rights or Licensed Products by Company, its Affiliates,
sublicensees, assignees or vendors or third parties, including, but not limited to, (x) any product
liability or other Claim of any kind related to use by a third party of a Licensed Product, (y) any
Claim by a third party that the practice of any of the Patent Rights or the design, composition,
manufacture, use, sale or other disposition of any Licensed Product infringes or violates any
patent, copyright, trade secret, trademark or other intellectual property right of such third
party, and (z) any Claim by a third party relating to clinical trials or studies for Licensed
Products; (b) any material breach of this Agreement by Company or its Affiliates or sublicensees;
and (c) the enforcement of this Article 11 by any Indemnified Party. The term “Claim” means any
charges, complaints, actions, suits, proceedings, hearings, investigations, claims or demands.

     11.2 Other Provisions. Company will not settle or compromise any Claim giving rise to
Liabilities in any manner that imposes any restrictions or obligations on Penn or grants any rights
to the Penn Patent Rights or the Licensed Products without Penn’s prior written consent. If Company
fails or declines to assume the defense of any Claim within thirty (30) days after notice of the
Claim, then Penn may assume the defense of such Claim for the account and at the risk of Company,
and any Liabilities related to such Claim will be conclusively deemed a liability of Company. The
indemnification rights of the Indemnified Parties under this Article 11 are in addition to all
other rights that an Indemnified Party may have at law, in equity or otherwise.

	12.	 	INSURANCE

     12.1 Coverages. Company will procure and maintain insurance policies for the following
coverages with respect to personal injury, bodily injury and property damage arising out of
Company’s performance under this Agreement: (a) during the Term, comprehensive general liability,
including broad form and contractual liability, in a minimum amount of $2,000,000 combined single
limit per occurrence and in the aggregate; (b) prior to the commencement of clinical trials
involving Licensed Products, clinical trials coverage in a minimum amount of $3,000,000 combined
single limit per occurrence and in the aggregate; and (c) prior to the Sale of the first Licensed
Product, product liability coverage, in a minimum amount of $2,000,000 combined single limit per
occurrence and in the aggregate. Penn may review periodically the adequacy of the minimum amounts
of insurance for each coverage required by this Section 12.1, and Penn reserves the right to
require Company to adjust the limits accordingly. The required minimum

12

 

Confidential

amounts of insurance do not constitute a limitation on Company’s liability or indemnification
obligations to Penn under this Agreement.

     12.2 Other Requirements. The policies of insurance required by Section 12.1 will be
issued by an insurance carrier with an A.M. Best rating of “A” or better and will name Penn as an
additional insured with respect to Company’s performance under this Agreement. Company will provide
Penn with insurance certificates evidencing the required coverage within thirty (30) days after the
Effective Date and the commencement of each policy period and any renewal periods. Each certificate
will provide that the insurance carrier will notify Penn in writing at least thirty (30) days prior
to the cancellation or material change in coverage.

	13.	 	ADDITIONAL PROVISIONS

     13.1 Independent Contractors. The parties are independent contractors. Nothing
contained in this Agreement is intended to create an agency, partnership or joint venture between
the parties. At no time will either party make commitments or incur any charges or expenses for or
on behalf of the other party.

     13.2 No Discrimination. Neither Penn nor Company will discriminate against any
employee or applicant for employment because of race, color, sex, sexual or affectional preference,
age, religion, national or ethnic origin, handicap, or veteran status.

     13.3 Compliance with Laws. Company must comply with all prevailing laws, rules and
regulations that apply to its activities or obligations under this Agreement. For example, Company
will comply with applicable United States export laws and regulations. The transfer of certain
technical data and commodities may require a license from the applicable agency of the United
States government and/or written assurances by Company that Company will not export data or
commodities to certain foreign countries without prior approval of the agency. Penn does not
represent that no license is required, or that, if required, the license will issue.

     13.4 Modification, Waiver & Remedies. This Agreement may only be modified by a
written amendment that is executed by an authorized representative of each party. Any waiver must
be express and in writing. No waiver by either party of a breach by the other party will
constitute a waiver of any different or succeeding breach. Unless otherwise specified, all remedies
are cumulative.

     13.5 Assignment & Hypothecation. Except in the case of a merger or consolidation with
another company or sale of all or substantially all of its assets or business to which the
Agreement relates, Company may not assign this Agreement or any part of it, either directly or by
merger or operation of law, without the prior written consent of Penn. Penn will not unreasonably
withhold or delay its consent, provided that: (a) at least thirty (30) days before the proposed
transaction, Company gives Penn written notice and such background information as may be reasonably
necessary to enable Penn to give an informed consent; (b) the assignee agrees in writing to be
legally bound by this Agreement and to deliver to Penn an updated Development Plan within
forty-five (45) days after the closing of the proposed transaction; and (c) Company provides Penn
with a copy of assignee’s undertaking. Any permitted assignment will not relieve Company of
responsibility for performance of any obligation of Company that has accrued at the

13

 

Confidential

time of the assignment. Company will not grant a security interest in the License or this
Agreement during the Term. Any prohibited assignment or security interest will be null and void.

     13.6 Notices. Any notice or other required communication (each, a “Notice”) must be
in writing, addressed to the party’s respective Notice Address listed on the signature page, and
delivered: (a) personally; (b) by certified mail, postage prepaid, return receipt requested; (c) by
recognized overnight courier service, charges prepaid; or (d) by facsimile. A Notice will be deemed
received: if delivered personally, on the date of delivery; if mailed, five (5) days after deposit
in the United States mail; if sent via courier, one (1) business day after deposit with the courier
service; or if sent via facsimile, upon receipt of confirmation of transmission provided that a
confirming copy of such Notice is sent by certified mail, postage prepaid, return receipt
requested.

     13.7 Severability & Reformation. If any provision of this Agreement is held to be
invalid or unenforceable by a court of competent jurisdiction, then the remaining provisions of
this Agreement will remain in full force and effect. Such invalid or unenforceable provision will
be automatically revised to be a valid or enforceable provision that comes as close as permitted by
law to the parties’ original intent.

     13.8 Headings & Counterparts. The headings of the articles and sections included in
this Agreement are inserted for convenience only and are not intended to affect the meaning or
interpretation of this Agreement. This Agreement may be executed in several counterparts, all of
which taken together will constitute the same instrument.

     13.9 Governing Law. This Agreement will be governed in accordance with the laws of
the Commonwealth of Pennsylvania, without giving effect to the conflict of law provisions of any
jurisdiction.

     13.10 Dispute Resolution. If a dispute arises between the parties concerning any
right or duty under this Agreement, then the parties will confer, as soon as practicable, in an
attempt to resolve the dispute. If the parties are unable to resolve the dispute amicably, then the
parties will submit to the exclusive jurisdiction of, and venue in, the state and Federal courts
located in the Eastern District of Pennsylvania with respect to all disputes arising under this
Agreement.

     13.11 Integration. This Agreement with its Exhibits and the Confidentiality Agreements,
contain the entire agreement between the parties with respect to the Patent Rights and the License
and supersede all other oral or written representations, statements, or agreements with respect to
such subject matter, including but not limited to the Term Sheet.

14

 

Confidential

Each party has caused this Agreement to be executed by its duly authorized representative.

	 	 	 	 	 	 	 	 

	THE TRUSTEES OF THE	 	NuPathe Inc.	 
	UNIVERSITY OF PENNSYLVANIA	 	 	 	 	 
	 
	 	 	 	 	 	 	 
	By:

	 	/s/ John Zawad
	 	By:
	 	/s/ Jane H. Hollingsworth	 
	 

	 	 
	 	 	 	 	 
	

	 	Name: John Zawad
	 	
	 	Name: J H Hollingsworth	 
	

	 	Title: Managing Director,
	 	
	 	Title: CEO	 

	 	 	 	 	 	 	 

	Address:

	 	Center for Technology Transfer
	 	Address:
	 	375 E. Elm Street
	 

	 	University of Pennsylvania
	 	 	 	Suite 110
	 

	 	3160 Chestnut Street, Suite 200
	 	 	 	Conshohocken, PA 19428
	 

	 	Philadelphia, PA 19104-6283
	 	 	 	Attention: General Counsel
	 

	 	Attention: Managing Director	 	 	 	 

	 	 	 

	Required copy to:

	 	University of Pennsylvania
	 

	 	Office of General Counsel
	 

	 	133 South 36th Street, Suite 300
	 

	 	Philadelphia, PA 19104-3246
	 

	 	Attention: General Counsel

15

 

Confidential

EXHIBIT INDEX

	 	 	 

	Exhibit A

	 	Patents and Patent Applications in Patent Rights
	 
	 	 
	Exhibit B

	 	Minimum Contents of Development Plan
	 
	 	 
	Exhibit C

	 	Format of Royalty Report
	 
	 	 
	Exhibit D

	 	Form of Patent Management Agreement

16

 

Confidential

EXHIBIT A

PATENT RIGHTS

	 	 	 	 	 	 	 	 	 	 	 
		 		 		 		 		 	Foreign
	Penn Docket	 	Disclosure Title	 	Inventors	 	Applicants	 	US Patents	 	Patents
	M2281

	 	Polymer-based Surgically Implantable Haloperidol Delivery
Systems and Methods for Their Production and Use
	 	Steven Siegel, Karen

Winey,

Robert

Lenox,

Raquel Gur
	 	Penn
	 	US Patent Application 60/242,304
	 	None
	 
	 	 	 	 	 	 	 	 	 	 
	Q3399-PCT

	 	Long-Term Delivery Formulations and Methods of Use Thereof
	 	Steve Siegel,

Karen Winey
	 	Penn
	 	PCT Application US05/00884	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	S4072

	 	Drug- Containing Implants and Methods of Use Thereof
	 	Steven Siegel, Karen Winey
	 	Penn
	 	US Provisional Patent

Application 11/183,232	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	S4084

	 	Drug containing Implants and Methods of Use Thereof
	 	Steven Siegel, Karen Winey
	 	Penn
	 	US Provisional Patent

Application 11/195,845	 	 

17

 

Confidential

EXHIBIT B

Development Plan Contents

The initial Development Plan and each update to the Development Plan will include, at a minimum,
the following information:

	 	•	 	The date of the Development Plan and the reporting period covered by the
Development Plan.
	 
	 	•	 	Identification and nature of each active relationship between Company and
its Affiliates, sublicensees or subcontractors in the research, development or
commercialization of Licensed Products or Penn Patent Rights
	 
	 	•	 	Significant projects completed during the reporting period by Company or
its Affiliates, sublicensees or subcontractors in the research, development or
commercialization of Licensed Products or Penn Patent Rights.
	 
	 	•	 	Significant projects currently being performed by Company or its
Affiliates, sublicensees or subcontractors in the research, development or
commercialization of Licensed Products or Penn Patent Rights.
	 
	 	•	 	Future projects expected to be undertaken during the next reporting period
by Company or its Affiliates, sublicensees or subcontractors in the research,
development or commercialization of Licensed Products or Penn Patent Rights.
	 
	 	•	 	Projected timelines to product launch of each Licensed Product prior to
first Sale.
	 
	 	•	 	Projected annual Net Sales for each Licensed Product after first Sale.
	 
	 	•	 	Significant changes to the current Development Plan since the previous
Development Plan and the reasons for the changes.
	 
	 	•	 	Significant assumptions underlying the Development Plan and the future
variables that may cause significant changes to the Development Plan.
	 
	 	•	 	Copies of all reports required by Section 4.5 of this Agreement that have
not already been delivered to Penn.

18

 

Confidential

	 	 	 

	

	 	Center for Technology Transfer
 University of Pennsylvania
 Royalty Report

	 	 	 	 	 	 

	Licensee:

	 	 	 	Agreement:	 
	 	 	 	 	 	 

	 	 	 	 	 	 
	Inventor:

	 	 	 	Patent #:	 
	 	 	 	 	 	 

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Period Covered: From:

	 	/
	 	/
	 		Through:	 	/
	 	/
	 

	 	 	 	 	 	 
	Prepared By:

	 	 	 	Date:	 
	 	 	 	 	 	 

	 	 	 	 	 	 
	Approved By:

	 	 	 	Date:	 
	 	 	 	 	 	 

If License covers several major product lines, please prepare a separate for each line. Then continue all product lines into a summary report.

	 	 	 	 	 

	Report Type:

	 	o
	 	Single Product Line Report:
	 

	 	o
	 	Multi-product Summary Report: Page 1 of                      Pages
	 

	 	o
	 	Product Line Detail: Line:                      Trade Name:                      Page:                     
	Report Currency:

	 	o
	 	U.S. Dollars            o Other                     

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	Gross	 	*Less:	 	Net	 	Royalty	 	Period Royalty Amount
	Country	 	Sales	 	Allowances	 	Sales	 	Rate	 	This Year	 	Last Year
	U.S.A
	 	 	 	 	 	 	 	 	 	 	 	 
	Canada
	 	 	 	 	 	 	 	 	 	 	 	 
	Europe
	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	Japan
	 	 	 	 	 	 	 	 	 	 	 	 
	Other
	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	Total:
	 	 	 	 	 	 	 	 	 	 	 	 

Total Royalty:                      Conversion Rate:                      Royalty in U.S. Dollars $     
          

     The following royalty forecast is non-binding and for CTT internal planning purposes only:

Royalty Forecast Under this agreement: Next Quarter: _____Q2: _____Q3: _____ Q4: _____

On a separate page, please indicate the reasons for returns or other adjustments if
significant.

Also note any unusual occurrences that affected royalty amounts during this period.

To assist CTT’s forecasting, please comment on any significant expected trends in sales volume

19

 

CONFIDENTIAL

UNIVERSITY OF PENNSYLVANIA

First Amendment To Patent License Agreement

     This First Amendment To The Patent License Agreement dated May 1, 2006
(“First Amendment”) is entered into by and between The Trustees of the University of Pennsylvania,
a Pennsylvania nonprofit corporation (“Penn”), and NuPathe Inc., a corporation organized and
existing under the laws of Delaware (“Company”).

BACKGROUND

     Whereas, Penn and Company (the “Parties”) have entered into that certain Patent License
Agreement effective July 1, 2006 (the “License Agreement”) pursuant to which Penn has licensed
certain Penn owned Patent Rights to Company; and

     Whereas, Company and Penn have a joint interest in a that certain patent application titled,
“Implants for the Treatment of Dopamine Associated States”, US No. 60/789,961 ( the “Ropinirole
Patent”); and

     Whereas, Company desires to obtain from Penn and Penn desires to grant to Company an exclusive
license to Penn’s interest in the Ropinirole Patent; and

     NOW, THEREFORE, for good and valuable consideration, AND INTENDING TO BE LEGALLY BOUND, Penn
and NuPathe hereby agree as follows:

1. Company will pay to Penn a non-refundable amendment fee of [**]
dollars ($[**]) immediately upon execution of this First Amendment.

	2.	 	Section 1.2 and Exhibit A

The following patent application is hereby added to Exhibit A to the License Agreement and
incorporated into the definition of Patent Rights as set forth in Section 1.2 of the License
Agreement:

	 	 	 	 	 	 	 	 	 
	Penn	 	 	 	 	 	 	 	 
	Docket	 	Disclosure Title	 	Inventors	 	Applicants	 	Application No.
	S4236

	 	Ropinerol Implants
for the Treatment
of Parkinson’s
Disease
	 	Terri B. Sebree, Steven Siegel
	 	NuPathe Inc.
	 	US No. 60/789,961

     A new Exhibit A is attached to this Amendment No. 1.

	3.	 	Section 3.3

     The following language is hereby added to Section 3.3:

For Penn Licensed Products that include an active ingredient that is ropinirole, the Active
Ingredient Multiplier =[**]. For clarity, the milestone payments for Penn Licensed

 

			
	**	 	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

 

 

CONFIDENTIAL

Products
that include an active ingredient that is ropinirole the Total Milestone Payments are:

	 	 	 

	[**]

	 	$[**]
	[**]

	 	$[**]
	[**]

	 	$[**]
	[**]

	 	$[**]
	 
	 	 
	[**]
	 	 

	4.	 	Section 3.4

The following language is hereby added to Section 3.4:

For Penn Licensed Products that include an Active Ingredient that is ropinirole, the Royalty
Multiplier = [**]. For clarity, for Penn Licensed Products that include an Active Ingredient
that is ropinirole the Total Royalty is [**]%.

	5.	 	Section 4.7

     The language is deleted and replaced, in its entirety with the following language:

     Place of Payment. All payments by Company are payable to “The Trustees of the University of
Pennsylvania” and will be made to the following addresses:

	 	 	 
	By Electronic Transfer:	 	By Check:
	Mellon Bank East

	 	The Trustees of the University of Pennsylvania
	ABA #31000037

	 	c/o Center for Technology Transfer
	Account Number: 2945020

	 	P.O. Box 7777-W3850
	c/o: CTT / T. Dunn

	 	Philadelphia, PA 19175-3850

6. This First Amendment, together with the License Agreement, constitute the entire agreement
between the parties. All other terms and provisions of the License Agreement, except as expressly
amended by this First Amendment, remain in full force and effect.

     IN WITNESS WHEREOF, the parties hereto have executed this First Amendment by their duly
authorized officers as of the date set forth below.

 

			
	**	 	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

2

 

CONFIDENTIAL

ACCEPTED AND APPROVED BY AND BETWEEN:

	 	 	 	 	 	 	 	 
	THE TRUSTEES OF THE	 	NUPATHE INC.	
	UNIVERSITY OF PENNSYLVANIA	 	 	 	 	
	 
	 	 	 	 	 	 	
	By:

	 	/s/ Michael Breton
	 	By:
	 	/s/ Jane H. Hollingsworth	
	 

	 	 
	 	 	 	 	
	

	 	Name: Michael Breton
	 	
	 	Name: Jane H. Hollingsworth	
	

	 	Title: Associate Vice Provost for Research and
Interim Director — CTT
	 	
	 	Title: CEO	

	 	 	 	 	 	 	 

	Address:

	 	Center for Technology Transfer
	 	Address:
	 	375 E. Elm Street
	 

	 	University of Pennsylvania
	 	 	 	Suite 110
	 

	 	3160 Chestnut Street,	 	 	 	Conshohocken, PA 19428
	 

	 	Suite 200	 	 	 	 
	 

	 	Philadelphia, PA 19104-6283	 	 	 	 

3

 

CONFIDENTIAL

EXHIBIT A

PATENT RIGHTS

	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	Foreign
	Penn Docket	 	Disclosure Title	 	Inventors	 	Applicants	 	US Patents	 	Patents
	M2281

	 	Polymer-based
Surgically
Implantable
Haloperidol
Delivery
Systems and
Methods for
Their Production
and Use
	 	Steven Siegel, Karen Winey, Robert Lenox. Raquel Gur
	 	Penn
	 	US Patent

Application

60/242,304
	 	None
	 
	 	 	 	 	 	 	 	 	 	 
	Q3399-PCT

	 	Long-Term
Delivery
Formulations
and Methods of
Use Thereof
	 	Steven Siegel,

Karen Winey
	 	Penn
	 	PCT

Application

US05/00884	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	S4072

	 	Drug-Containing
Implants and
Methods od Use
Thereof
	 	Steven Siegel,

Karen Winey
	 	Penn
	 	US

Provisional

Patent

Application

11/183,232	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	S4084

	 	Drug containing
Implants and
Methods of Use
Thereof
	 	Steven Siegel,

Karen Winey
	 	Penn
	 	US

Provisional

Patent

Application

11/195,845	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	S4236

	 	Ropinerol
Implants for the
Treatment of
Parkinson’s
Disease
	 	Steven Siegel, Terri Sebree
	 	NuPathe,
Inc.
	 	US No.
60/789,961	 	 

4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00174-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00174-of-00352.parquet"}]]